NasdaqGS:ONCBiotechs
BeOne Medicines (ONC) Stock Looks Expensive After A 72% Run
BeOne Medicines has delivered a strong 72.1% share price gain over the past three years, yet current checks flag the stock as screening on the expensive side based on market multiples and a mixed overall value score. For investors, that raises the question of whether recent fundamental milestones are already largely reflected in the current price.
A 72.1% return over three years points to strong shareholder gains, which can limit the margin of safety if expectations stay high.
Recent...